Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to test whether a combination treatment of Trametinib,
Retifanlimab, and Ruxolitinib (TR^2) will reduce tumor size in patients with metastatic
pancreatic ductal adenocarcinoma (PDAC).
Phase:
Phase 1
Details
Lead Sponsor:
Peter Hosein, MD
Collaborators:
Incyte Corporation Novartis Pharmaceuticals University of Miami Sylvester Comprehensive Cancer Center